Yasuyuki Kinoshita1, Fumiyuki Yamasaki2, Akira Taguchi2, Takeshi Takayasu2, Ushio Yonezawa2, Atsushi Tominaga3, Kazunori Arita4, Satoshi Okada5, Nobutaka Horie2, Kazuhiko Sugiyama6. 1. Department of Neurosurgery, Graduate School of Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, 7348551, Japan. y-kinoshita@hiroshima-u.ac.jp. 2. Department of Neurosurgery, Graduate School of Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, 7348551, Japan. 3. Department of Neurosurgery and Neuro-Endovascular Therapy, Hiroshima Prefectural Hospital, Hiroshima, Japan. 4. Department of Neurosurgery, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan. 5. Department of Pediatrics, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan. 6. Department of Clinical Oncology and Neuro-Oncology Program, Hiroshima University Hospital, Hiroshima, Japan.
Abstract
PURPOSE: Due to the effectiveness of growth hormone therapy (GHT), the number of cancer survivors receiving GHT has increased. Previous studies had indicated that GHT was not associated with the increasing risks of tumor recurrence and development with second neoplasm (SN) in cancer survivors. However, to date, research on those risks in germinoma survivors is still limited. The aim of this study is to evaluate the impact of GHT in relation to tumor recurrence and development with SN in pure germinoma survivors. METHODS: This retrospective cohort study was approved by the Ethical Committee for Epidemiology of our institution. Seventy-three consecutive patients who underwent a biopsy of the lesion and were diagnosed with pure germinoma were retrospectively studied. They (median age, 15.0 years) were followed up more than 1 year after biopsy (median follow-up period, 14.3 years). The following data was obtained from the medical records of the patients: age, sex, preoperative magnetic resonance imaging findings, hormonal replacement, and events including tumor recurrence and/or SN. RESULTS: In our patient series, 16 patients (21.9%) who were more likely to have neurohypophysial lesion and receive multiple hormonal therapies had received GHT. No significant differences in the rates of tumor recurrence and development with SN were observed between the patients who had and had not received GHT. Moreover, the recurrence-free survival and overall survival rates were not different between the patients who had and had not received GHT. CONCLUSIONS: GHT did not increase the risks of tumor recurrence and development with SN in pure germinoma survivors.
PURPOSE: Due to the effectiveness of growth hormone therapy (GHT), the number of cancer survivors receiving GHT has increased. Previous studies had indicated that GHT was not associated with the increasing risks of tumor recurrence and development with second neoplasm (SN) in cancer survivors. However, to date, research on those risks in germinoma survivors is still limited. The aim of this study is to evaluate the impact of GHT in relation to tumor recurrence and development with SN in pure germinoma survivors. METHODS: This retrospective cohort study was approved by the Ethical Committee for Epidemiology of our institution. Seventy-three consecutive patients who underwent a biopsy of the lesion and were diagnosed with pure germinoma were retrospectively studied. They (median age, 15.0 years) were followed up more than 1 year after biopsy (median follow-up period, 14.3 years). The following data was obtained from the medical records of the patients: age, sex, preoperative magnetic resonance imaging findings, hormonal replacement, and events including tumor recurrence and/or SN. RESULTS: In our patient series, 16 patients (21.9%) who were more likely to have neurohypophysial lesion and receive multiple hormonal therapies had received GHT. No significant differences in the rates of tumor recurrence and development with SN were observed between the patients who had and had not received GHT. Moreover, the recurrence-free survival and overall survival rates were not different between the patients who had and had not received GHT. CONCLUSIONS: GHT did not increase the risks of tumor recurrence and development with SN in pure germinoma survivors.
Authors: Kevin C J Yuen; Beverly M K Biller; Sally Radovick; John D Carmichael; Sina Jasim; Kevin M Pantalone; Andrew R Hoffman Journal: Endocr Pract Date: 2019-11 Impact factor: 3.443
Authors: Sina Jasim; Fares Alahdab; Ahmed T Ahmed; Shrikant U Tamhane; Anu Sharma; Diane Donegan; Todd B Nippoldt; M Hassan Murad Journal: Endocrine Date: 2016-11-04 Impact factor: 3.633
Authors: Shrikant Tamhane; Jad G Sfeir; Nana Esi N Kittah; Sina Jasim; Wassim Chemaitilly; Laurie E Cohen; M Hassan Murad Journal: J Clin Endocrinol Metab Date: 2018-08-01 Impact factor: 5.958
Authors: D S Olsson; M Buchfelder; K Wiendieck; N Kremenevskaja; B-Å Bengtsson; K-E Jakobsson; M Jarfelt; G Johannsson; A G Nilsson Journal: Eur J Endocrinol Date: 2012-03-28 Impact factor: 6.664
Authors: Nawaf M Alotaibi; Nadia Noormohamed; David J Cote; Salman Alharthi; Joanne Doucette; Hasan A Zaidi; Rania A Mekary; Timothy R Smith Journal: World Neurosurg Date: 2017-10-04 Impact factor: 2.104